Pharma-telehealth partnerships like Novo Nordisk's subscription model reflect broader systemic shifts in healthcare access and profit structures
Original framing: “STAT+: Novo’s subscription model raises questions about pharma-telehealth tie-ups” — STAT News
Patients in low-income and rural areas, as well as those with chronic conditions, are often excluded from the design and implementation of telehealth models. Their lived experiences are critical for understanding how these models affect access, trust, and health outcomes.
The Novo Nordisk subscription model is not an isolated business experiment but a symptom of a broader shift in healthcare where pharmaceutical companies are leveraging digital infrastructure to control treatment access.
This trend reflects historical patterns of corporate consolidation in health, where profit motives often override public health imperatives. Cross-culturally, the model contrasts with more community-centered approaches seen in parts of Africa and Asia, where telehealth is used to expand access rather than restrict it. Indigenous and marginalized voices highlight the need for healthcare models that prioritize relational and holistic care over transactional delivery. To avoid deepening health inequities, regulatory bodies and public health institutions must intervene to ensure that digital health innovations serve the public good, not just corporate interests.